Novo Nordisk A/S (NYSE:NVO) Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 232,166 shares of the company’s stock after selling 4,231 shares during the period. Trillium Asset Management LLC’s holdings in Novo Nordisk A/S were worth $19,971,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Cassaday & Co Wealth Management LLC purchased a new stake in Novo Nordisk A/S in the 3rd quarter valued at approximately $235,000. Baron Wealth Management LLC lifted its stake in Novo Nordisk A/S by 18.8% in the 3rd quarter. Baron Wealth Management LLC now owns 3,224 shares of the company’s stock valued at $384,000 after buying an additional 510 shares in the last quarter. Aviance Capital Partners LLC lifted its stake in Novo Nordisk A/S by 4.7% in the 3rd quarter. Aviance Capital Partners LLC now owns 17,091 shares of the company’s stock valued at $2,035,000 after buying an additional 770 shares in the last quarter. Pathstone Holdings LLC lifted its stake in Novo Nordisk A/S by 0.3% in the 3rd quarter. Pathstone Holdings LLC now owns 290,229 shares of the company’s stock valued at $34,558,000 after buying an additional 734 shares in the last quarter. Finally, Caprock Group LLC purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $7,293,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the topic of a number of recent analyst reports. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 13th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Up 1.0 %

Shares of NVO opened at $80.95 on Wednesday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $363.28 billion, a P/E ratio of 24.61, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The stock’s fifty day simple moving average is $83.81 and its 200 day simple moving average is $101.98. Novo Nordisk A/S has a twelve month low of $73.80 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.